Clinical Diagnosis

The diagnosis of epidermolysis bullosa with pyloric atresia (EB-PA) is suspected in newborns with the following:

• Fragility of the skin with:

  • Blistering with little or no trauma. Blistering may be mild or severe; however, blisters generally heal with no significant scarring.

  • Significant oral and mucous membrane involvement

• Congenital pyloric atresia with vomiting and abdominal distension resulting from complete obstruction of the gastric outlet. Radiographs reveal that the stomach is distended and filled with air (see Figure 1).

• Ureteral and renal anomalies, including hydronephrosis, ureterocele, absent bladder, dysplastic kidneys, urinary collecting system/kidney duplication, obstructive uropathy, glomerulosclerosis

Figure

Figure 1. Radiograph of a 36-week gestational-age, one-day-old neonate with EB-PA. Note the single gastric bubble (white arrow).

Because the clinical features of all types of epidermolysis bullosa (EB) overlap significantly (see Differential Diagnosis), clinical diagnosis is unreliable and examination of a skin biopsy is usually required to establish the diagnosis of EB-PA, especially in infants.

Testing

Skin biopsy. Examination of a skin biopsy by transmission electron microscopy (TEM) and/or immunofluorescent antibody/antigen mapping is the best way to reliably establish the diagnosis of EB-PA.

A punch biopsy that includes the full basement membrane zone is preferred. The biopsy should be taken from the leading edge of a fresh (<12 hours old) or mechanically induced blister and should include some normal adjacent skin. (Older blisters undergo change that may obscure the diagnostic morphology).

Note:

(1) For TEM
(a) Specimens must be placed in fixation medium (such as gluteraldehyde) as designated by the laboratory performing the test.
(b) Formaldehyde-fixed samples cannot be used for electron microscopy

(2) For immunofluorescent antibody/antigen mapping
(a) Specimens should be sent in sterile carrying medium (such as Michel's of Zeus) as specified by the laboratory performing the test.
(b) Some laboratories prefer flash-frozen tissue.
(c) In some laboratories the mapping only designates the level of the cleavage by using various marker antibodies of different layers of the basement membrane. A laboratory that has the antigens for the proteins of interest in EB is preferred because both the level of cleavage and the presence or absence of the specific gene products mutated in EB can be assessed.

(3) Light microscopy is inadequate and unacceptable for the accurate diagnosis of EB.

Transmission electron microscopy (TEM) is used to examine the number and morphology of the basement membrane zone structures — in particular, the number and morphology of anchoring fibrils, the presence of and morphology of hemidesmosomes, anchoring filaments, and keratin intermediate filaments as well as the presence of micro-vessicles showing the tissue cleavage plane.

Findings on TEM in EB-PA include the following:

• Cleavage may be within the lamina lucida or just above the hemidesmosomes in the lowest layer of the basal keratinocytes.

• Hemidesmosomes may be reduced in number or dysmorphic [Kunz et al 2000, Jonkman et al 2002, Charlesworth et al 2003, Pasmooij et al 2004].

Immunofluorescent antibody/antigen mapping. Findings include the following:

• Abnormal or absent staining with antibodies to α6β4 integrin in EB-PA and other rare forms of junctional epidermolysis bullosa (JEB) as a result of mutations in either ITGA6 or ITGB4

• Abnormal or absent staining with antibodies to plectin in EB-PA as a result of PLEC1 mutations

Normal staining for other antigens (e.g., collagen VII, laminin 332, keratins 5 and 14) confirms the diagnosis of EB-PA.

Note: Especially in milder forms of EB, indirect immunofluorescent studies are often not sufficient to make the diagnosis because near-normal antigen levels are detected and no cleavage plane is observed. In addition, absence of one hemidesmosomal component (e.g., ITGA6 or ITGB4) may reduce the staining of other hemidesmosomal components as well (e.g., PLEC1, COL17). In these cases electron microscopic examination of a skin biopsy must be performed.

Molecular Genetic Testing

Genes. Mutations in three genes are known to cause EB-PA [Nakamura et al 2005, Pfendner & Uitto 2005, Pfendner et al 2005, Varki et al 2006, Pfendner et al 2007]:

• ITGB4 accounts for ~80% of EB-PA

• ITGA6 accounts for ~5% of EB-PA

• PLEC1 accounts for ~15% of EB-PA

Clinical testing

• Sequence analysis

  • ITGB4. Sequencing of ITGB4 detects more than 98% of ITGB4 mutations.

  • ITGA6. Sequencing of ITGA6 detects more than 98% of ITGA6 mutations overall.

  • PLEC1. Sequencing of PLEC1 detects more than 98% of PLEC1 mutations.

• Deletion/duplication analysis

  • ITGB4. No large deletions or duplications have been reported in ITGB4. Based on the high sensitivity of the ITGB4 sequencing test, a screening test for large deletions/duplications is expected to have a very low yield.

  • ITGA6. No large insertions or deletions have been reported in ITGA6. Based on the high sensitivity of the ITGA6 sequencing test, a screening test for large deletions/duplications is expected to have a very low yield.

Table 1. Summary of Molecular Genetic Testing Used in Epidermolysis Bullosa with Pyloric Atresia

View in own window

Gene Symbol	Proportion of EB-PA Attributed to Mutations in This Gene 1	Test Method	Mutation Detection Frequency by Gene and Test Method 2	Test Availability
ITGB4	80%	Sequence analysis	>98% 3	Clinical
		Deletion/duplication analysis 4	<1%
ITGA6	5%	Sequence analysis	>98%	Clinical
		Deletion/duplication analysis 4	<1%
PLEC1	15%	Sequence analysis	>98%	Clinical

1. Varki et al [2006]

2. Test Availability refers to availability in the GeneTests^TM Laboratory Directory. GeneReviews designates a molecular genetic test as clinically available only if the test is listed in the GeneTests^TM Laboratory Directory by either a US CLIA-licensed laboratory or a non-US clinical laboratory. GeneTests does not verify laboratory-submitted information or warrant any aspect of a laboratory's licensure or performance. Clinicians must communicate directly with the laboratories to verify information.

3. 50% of persons of Hispanic heritage in the US have the ITGB4 mutation p.Cys61Tyr [Varki et al 2006].

4. Although no large deletions/duplications have been reported in these genes, such testing would be expected to detect exonic, multiexonic, and whole-gene deletions/duplications.

Interpretation of test results. For issues to consider in interpretation of sequence analysis results, click here.

Testing Strategy

Confirmation of the diagnosis in a proband. The skin biopsy should be used to guide the molecular genetic testing strategy:

• If the α6β4 integrin protein is reduced or absent on immunofluorescent antibody/antigen mapping and the cleavage plane on TEM is within the lamina lucida, most often mutations in ITGB4 are responsible and molecular genetic testing of ITGB4 should be pursued.

• If no ITGB4 mutations are identified and the biopsy suggests by immunofluorescent antibody/antigen mapping that the α6β4 integrin protein is affected, molecular genetic testing of ITGA6 may be pursued.

• In some cases the cleavage plane on TEM may be just above the hemidesmosomes in the lowest keratinocyte layer and plectin staining is reduced or absent on immunofluorescent antibody/antigen mapping [Charlesworth et al 2003, Nakamura et al 2004, Pfendner & Uitto 2005]. In these cases PLEC1 sequencing should be undertaken before ITGA6.

Carrier testing for at-risk relatives (in families with autosomal recessive inheritance) requires prior identification of the disease-causing mutations in the family.

Note: Carriers are heterozygotes for an autosomal recessive disorder and are not at risk of developing the disorder.

Prenatal diagnosis and preimplantation genetic diagnosis (PGD) for at-risk pregnancies require prior identification of the disease-causing mutations in the family.

Note: It is the policy of GeneReviews to include in GeneReviews^TM chapters any clinical uses of testing available from laboratories listed in the GeneTests^TM Laboratory Directory; inclusion does not necessarily reflect the endorsement of such uses by the author(s), editor(s), or reviewer(s).

Genetically Related (Allelic) Disorders

ITGB4. Mutations in ITGB4 can result in EB-PA, EBS (rare), or JEB (rare) [Inoue et al 2000, Jonkman et al 2000].

ITGA6. EB-PA is the only phenotype associated with mutations in ITGA6.

PLEC1. The other phenotypes associated with PLEC1 mutations:

• EB with muscular dystrophy (EB-MD) [OMIM 226670, Charlesworth et al 2003, Koss-Harnes et al 2004, Schara et al 2004, Pfendner et al 2005]. Approximately 50 cases of EB-muscular dystrophy (EB-MD) have been reported worldwide. Blistering occurs early and is generally mild. Muscular dystrophy may not appear until later childhood, adolescence, or in some cases adulthood, and can cause immobility and eventually death later in life. Mutations have been described throughout PLEC1 but seem to cluster in the two long open reading frames containing exons in the 3' end of the gene. Nonsense, missense, insertion/deletion, and splice junction mutations have been described. The mildest phenotypes are usually associated with in-frame insertions or deletions, which do not alter the reading frame of the mRNA [Pfendner et al 2005]. Inheritance is autosomal recessive.

• EB simplex-Ogna (see Epidermolysis Bullosa Simplex), observed in one Norwegian and one German family with autosomal dominant inheritance, is a result of the site-specific missense p.Arg2110Trp mutation within the rod domain of PLEC1 [Koss-Harnes et al 2002]. A single lethal case of autosomal recessive EBS resulting from PLEC1 mutations has also been described [Charlesworth et al 2003]. Kunz et al [2000] also described a case of EBS with severe mucous membrane involvement as a result of mutations in PLEC1.

Natural History

The course of epidermolysis bullosa with pyloric atresia (EB-PA) is usually severe and often lethal in the neonatal period. Infants with extensive aplasia cutis congenita and blistering or erosions may have fatal infections with sepsis and severe electrolyte imbalance in the first weeks to months of life.

Although most affected children succumb as neonates, those who survive may have severe blistering with formation of granulation tissue on the skin around the mouth, nose, fingers, and toes, and internally around the trachea. However, some affected individuals have little or no blistering later in life.

Although mutations in ITGB4, ITGA6, and plectin usually result in EB-PA, there are also rare reports of ITGB4 resulting in milder forms of EB described as EBS and JEB [Inoue et al 2000, Jonkman et al 2000]. Although plectin mutations causing EB-PA usually result in severe blistering associated with PA, other mutations result in milder blistering and the disorders EBS Ogna and EB-MD.

Pyloric atresia may be detected in utero as oligohydramnios. Pyloric atresia is evident at birth and is characterized by vomiting, failure to tolerate any feeding or to pass stool, and a distended abdomen with a large stomach bubble (see Figure 1). Surgical repair of the pyloric atresia is necessary for survival.

Renal and ureteral anomalies can include dysplastic/multicystic kidney, hydronephrosis/hydroureter, acute renal tubular necrosis, obstructive uropathy, ureterocele, duplicated renal collecting system, and absent bladder [Puvabanditsin et al 1997, Kambham et al 2000, Nakano et al 2000, Wallerstein et al 2000, Varki et al 2006, Pfendner et al 2007].

The long-term prognosis of EB-PA depends on the severity of the cutaneous manifestations.

Manifestations that can occur in EB-PA as well as junctional epidermolysis bullosa Herlitz (H-JEB) and non-Herlitz (NH-JEB) types, dystrophic epidermolysis bullosa (DEB), and epidermolysis bullosa simplex (EBS). The following manifestations are now recognized to be found in the major EB types as described in the findings of the National EB Registry [Fine et al 1999]:

• Congenital localized absence of skin (aplasia cutis congenita) can be seen in any of the major types of EB and is not a discriminating diagnostic feature of any of these types of EB in general or any subtype of JEB. Congenital absence of skin on the extremities had been classified as Bart syndrome [OMIM 132000] but currently is considered a manifestation of all types of EB.

• Milia are small white-topped papules; they are often confused with epidermal cysts and are not confined to any type of EB, although they are most common in individuals with DEB.

• Nail dystrophy is defined as changes in size, color, shape, or texture of nails and is not confined to any one form of EB.

• Scarring alopecia is defined as complete loss of scalp hair follicles as a result of scarring and loss of hair follicles. Scarring alopecia is more prevalent in JEB and DEB but is not confined solely to any one form of EB.

• Hypotrichosis is defined as reduction in the number of hair follicles in a given area compared to the number of hair follicles in the same area of a normal individual of the same gender. Hypotrichosis is not confined to any one form of EB.

• Pseudosyndactyly and other contractures. Pseudosyndactyly is defined as the partial or complete loss of web spaces between any digits of the hands or feet. "Other contractures" refers to loss of mobility of any other joints as a result of fibrous tissue scars. Although these changes are more prevalent in DEB, they have also been observed occasionally in the other forms of EB.

• Scarring is not confined to any form of EB and has been observed in 30% of those with EBS, 76% of those with JEB, and up to 98% of those with DEB.

• Exuberant granulation tissue. Although exuberant granulation tissue was previously thought to be confined to those with JEB (23%), it has also been observed in a small percentage of those with DEB (≤12%) and EBS (0.7%). This finding is misleading because it does not usually appear until the affected child is a few years old and most children with H-JEB do not survive that long.

Genotype-Phenotype Correlations

The forms of EB-PA with the severest cutaneous manifestations are caused by mutations that result in premature termination codons on both alleles, although a number of amino acid substitutions also result in a severe phenotype such as the recurrent ITGB4 mutation p.Cys61Tyr in Hispanic individuals with EB-PA [Varki et al 2006].

Individuals with EB-PA mutations in the genes encoding α6 or β4 integrin may also show renal and ureteral anomalies.

Penetrance

Mutations in ITGB4, ITGA6, and PLEC1 are 100% penetrant in individuals who have two mutations on different alleles in the same gene.

Although PLEC1 mutations may result in several different phenotypes (EB-MD, EBS, and EB-PA) and ITGB4 mutations may result in EB without pyloric atresia, all individuals with mutations in ITGB4, ITGA6, and PLEC1 exhibit skin blisters.

Prevalence

According to the National EB Registry, prevalence of all types of JEB is 0.44 per million in the US population [Fine et al 1999]. Historically, EB-PA was considered a subclass of JEB; however, EB-PA is rare and its prevalence and incidence have not been determined.

Evaluations Following Initial Diagnosis

To establish the extent of disease in an individual diagnosed with epidermolysis bullosa with pyloric atresia (EB-PA), the following evaluations are recommended:

• Evaluation of the sites of blister formation including skin and oral mucosa

• Renal ultrasound examination and tests of renal function

• Delineation of involvement of the upper esophagus by barium swallow or endoscopy as needed

Treatment of Manifestations

Skin. New blisters should be lanced and drained to prevent further spread from fluid pressure.

In most cases, dressings for blisters involve three layers:

• A primary nonadherent dressing that does not strip the top layers of the epidermis. Tolerance to different primary layers varies. Primary layers include the following:

  • Ordinary Band-Aids^®

  • Dressings impregnated with an emollient such as petrolatum or topical antiseptic (e.g., Vaseline^® gauze, Adaptic^®, Xeroform^®)

  • Nonstick products (e.g., Telfa^®, N-terface^®)

  • Silicone-based products without adhesive (e.g., Mepitel^®, Mepilex^®)

• A secondary layer that provides stability for the primary layer and adds padding to allow more activity. Rolls of gauze (e.g., Kerlix^®) are commonly used.

• A tertiary layer that usually has some elastic properties and ensures the integrity of the dressing (e.g., Coban^® or elasticized tube gauze of varying diameters such as Band Net^®)

GI tract. Surgical intervention is required to correct pyloric atresia.

Esophageal strictures and webs can be dilated repeatedly to improve swallowing [Azizkhan et al 2007].

Other. A hoarse cry in an infant should alert to the possibility of airway obstruction with granulation tissue. Decisions about tracheostomy should involve the family and take into consideration the medical condition of the infant. Because of the poor prognosis and severe pain and discomfort experienced by these infants, a discussion with the family and hospital ethics committee often helps to determine the type of intervention and comfort care to provide [Yan et al 2007].

Some children have delays or difficulty walking because of blistering and hyperkeratosis. Appropriate footwear and physical therapy are essential to preserve ambulation.

Psychosocial support, including social services and psychological counseling, is essential [Lucky et al 2007].

Dental care is necessary because of inherent enamel abnormalities [Kirkham et al 2000].

Prevention of Secondary Complications

The most common secondary complication is infection. In addition to wound care, treatment of chronic infection of wounds is a challenge. Many affected individuals become infected with resistant bacteria, most often methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Both antibiotics and antiseptics need to be employed.

Fluid and electrolyte problems, which can be significant and even life threatening in the neonatal period and in infants with widespread disease, require careful management.

In children who survive the newborn period, nutritional deficiencies must also be addressed when they are identified:

• Calcium and vitamin D replacement for osteopenia and osteoporosis

• Zinc supplementation for wound healing [Mellerio et al 2007]

Iron-deficiency anemia, a chronic problem, can be treated with oral or intravenous iron infusions and red blood cell transfusions.

Surveillance

Screening for iron-deficiency anemia should be routine with complete blood counts and possibly measurement of serum iron concentration to provide iron supplementation when necessary.

Screening for zinc deficiency by measuring serum zinc concentration should be routine to provide zinc supplementation when necessary to enhance wound healing.

Screening with bone mineral density scanning may pick up early osteopenia and/ or osteoporosis. No guidelines have been established regarding the age at which this should begin.

Because of the risk for squamous cell carcinoma, surveillance in the second decade of life for wounds that do not heal, have exuberant scar tissue, or otherwise look abnormal is essential. Frequent biopsies of suspicious lesions may be necessary followed by local excision.

Agents/Circumstances to Avoid

Most persons with EB-PA cannot use ordinary medical tape or Band-Aids^®.

Poorly fitting or coarse-textured clothing and footwear should be avoided as they can cause trauma.

Activities that, in general, traumatize the skin (e.g., hiking, mountain biking, contact sports) should be avoided; affected individuals who are determined to participate in such activities should be encouraged to find creative ways to protect their skin.

Testing of Relatives at Risk

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Therapies Under Investigation

See Junctional Epidermolysis Bullosa, Management, Therapies Under Investigation.

Search ClinicalTrials.gov for access to information on clinical studies for a wide range of diseases and conditions.

Other

Cesarean section is often recommended to reduce trauma to the skin of an affected fetus during delivery.

Genetics clinics, staffed by genetics professionals, provide information for individuals and families regarding the natural history, treatment, mode of inheritance, and genetic risks to other family members as well as information about available consumer-oriented resources. See the GeneTests Clinic Directory.

See Consumer Resources for disease-specific and/or umbrella support organizations for this disorder. These organizations have been established for individuals and families to provide information, support, and contact with other affected individuals.

Mode of Inheritance

Epidermolysis bullosa with pyloric atresia (EB-PA) is inherited in an autosomal recessive manner.

To date, there is no evidence to indicate that a heterozygous mutation in ITGB4, ITGA6, or PLEC1 results in EB-PA.

Risk to Family Members

Parents of a proband

• The parents of an affected child are usually obligate heterozygotes and therefore each parent carries one mutant allele. Because germline mosaicism and uniparental isodisomy have been reported in JEB [Pulkkinen et al 1997a, Takizawa et al 2000, Cserhalmi-Friedman et al 2002, Fassihi et al 2005] and could be found in EB-PA, carrier status of parents needs to be confirmed with molecular genetic testing.

• Heterozygotes (carriers) are asymptomatic.

Sibs of a proband

• At conception, each sib of an affected individual whose parents are both carriers has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.

• Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.

• Heterozygotes (carriers) are asymptomatic.

Offspring of a proband. The offspring of an individual with EB-PA are obligate heterozygotes (carriers) for a disease-causing mutation.

Other family members of a proband. Each sib of the proband's carrier parents is at a 50% risk of being a carrier.

Carrier Detection

Carrier testing for at-risk family members is available on a clinical basis once the mutations have been identified in the family.

Related Genetic Counseling Issues

Family planning

• The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.

• It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk of being carriers.

DNA banking. DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, mutations, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals. DNA banking is particularly relevant when the sensitivity of currently available testing is less than 100%. See for a list of laboratories offering DNA banking.

Prenatal Testing

Molecular genetic testing. Prenatal testing for pregnancies at increased risk for EB-PA is possible by analysis of DNA extracted from fetal cells obtained by amniocentesis usually performed at approximately 15 to 18 weeks' gestation or chorionic villus sampling (CVS) at approximately ten to 12 weeks' gestation. The disease-causing alleles must be identified before prenatal testing can be performed.

Note: Gestational age is expressed as menstrual weeks calculated either from the first day of the last normal menstrual period or by ultrasound measurements.

Ultrasound examination. Occasionally pyloric atresia may be suspected because of oligohydramnios, with or without elevated concentration of alpha-fetoprotein and acetylcholinesterase, and echogenic material in the amniotic fluid [Dolan et al 1993, Azarian et al 2006].

Fetoscopy. Electron microscopic evaluation of fetal skin biopsies obtained by fetoscopy is also diagnostic in EB-PA. Fetoscopy carries a greater risk to pregnancy than CVS or amniocentesis and is performed relatively late (18-20 weeks) in gestation. Prenatal diagnosis for EB-PA using fetoscopy is not currently available in the US but may be available in Europe.

Preimplantation genetic diagnosis (PGD) may be available for families in which the disease-causing mutations have been identified. For laboratories offering PGD, see .

Note: It is the policy of GeneReviews to include in GeneReviews^TM chapters any clinical uses of testing available from laboratories listed in the GeneTests^TM Laboratory Directory; inclusion does not necessarily reflect the endorsement of such uses by the author(s), editor(s), or reviewer(s).

Literature Cited

1. Anton-Lamprecht I, Gedde-Dahl T (2002) Epidermolysis Bullosa in Principles and Practice of Medical Genetics, 4th edition. Rimoin DL, Connor MJ, Pyeritz RE, Korf BR, Emery AEH (eds) Churchill Livingstone Publishers, New York.
2. Ashton GH, Sorelli P, Mellerio JE, Keane FM, Eady RA, McGrath JA. Alpha 6 beta 4 integrin abnormalities in junctional epidermolysis bullosa with pyloric atresia. Br J Dermatol. 2001;144:408–14. [PubMed: 11251584]
3. Azarian M, Dreux S, Vuillard E, Meneguzzi G, Haber S, Guimiot F, Muller F. Prenatal diagnosis of inherited epidermolysis bullosa in a patient with no family history: a case report and literature review. Prenat Diagn. 2006;26:57–9. [PubMed: 16378325]
4. Azizkhan RG, Denyer JE, Mellerio JE, Gonzalez R, Bacigalupo M, Kantor A, Passalacqua G, Palisson F, Lucky AW. Surgical management of epidermolysis bullosa: Proceedings of the IInd International Symposium on Epidermolysis Bullosa, Santiago, Chile, 2005. Int J Dermatol. 2007;46:801–8. [PubMed: 17651160]
5. Charlesworth A, Gagnoux-Palacios L, Bonduelle M, Ortonne JP, De Raeve L, Meneguzzi G. Identification of a lethal form of epidermolysis bullosa simplex associated with a homozygous genetic mutation in plectin. J Invest Dermatol. 2003;121:1344–8. [PubMed: 14675180]
6. Chavanas S, Gache Y, Vailly J, Kanitakis J, Pulkkinen L, Uitto J, Ortonne J, Meneguzzi G. Splicing modulation of integrin beta4 pre-mRNA carrying a branch point mutation underlies epidermolysis bullosa with pyloric atresia undergoing spontaneous amelioration with ageing. Hum Mol Genet. 1999;8:2097–105. [PubMed: 10484780]
7. Chung J, Yoon SO, Lipscomb EA, Mercurio AM. The Met receptor and alpha 6 beta 4 integrin can function independently to promote carcinoma invasion. J Biol Chem. 2004;279:32287–93. [PubMed: 15161909]
8. Cserhalmi-Friedman PB, Anyane-Yeboa K, Christiano AM. Paternal germline mosaicism in Herlitz junctional epidermolysis bullosa. Exp Dermatol. 2002;11:468–70. [PubMed: 12366701]
9. Dolan CR, Smith LT, Sybert VP. Prenatal detection of epidermolysis bullosa letalis with pyloric atresia in a fetus by abnormal ultrasound and elevated alpha-fetoprotein. Am J Med Genet. 1993;47:395–400. [PubMed: 7510931]
10. Fassihi H, Wessagowit V, Ashton GH, Moss C, Ward R, Denyer J, Mellerio JE, McGrath JA. Complete paternal uniparental isodisomy of chromosome 1 resulting in Herlitz junctional epidermolysis bullosa. Clin Exp Dermatol. 2005;30:71–4. [PubMed: 15663509]
11. Fine JD, Bauer EA, McGuire J, Moshell A (eds) (1999) Epidermolysis Bullosa; Clinical epidemiologic, and laboratory advances and the findings of the National Epidermolysis Bullosa Registry, Johns Hopkins University Press, Baltimore.
12. Fine JD, Eady RA, Bauer EA, Briggaman RA, Bruckner-Tuderman L, Christiano A, Heagerty A, Hintner H, Jonkman MF, McGrath J, McGuire J, Moshell A, Shimizu H, Tadini G, Uitto J. Revised classification system for inherited epidermolysis bullosa: Report of the Second International Consensus Meeting on diagnosis and classification of epidermolysis bullosa. J Am Acad Dermatol. 2000;42:1051–66. [PubMed: 10827412]
13. Folgiero V, Bachelder RE, Bon G, Sacchi A, Falcioni R, Mercurio AM. The alpha6beta4 integrin can regulate ErbB-3 expression: implications for alpha6beta4 signaling and function. Cancer Res. 2007;67:1645–52. [PubMed: 17308105]
14. Gache Y, Romero-Graillet C, Spadafora A, Lepinard C, Descamps P, Bardon CB, Ortonne JP, Meneguzzi G. A novel homozygous mutation affecting integrin alpha6 in a case of junctional epidermolysis bullosa with pyloric atresia detected in utero by ultrasound examination. J Invest Dermatol. 1998;111:914–6. [PubMed: 9804362]
15. Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G, Giancotti FG. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell. 2006;126:489–502. [PubMed: 16901783]
16. Iacovacci S, Cicuzza S, Odorisio T, Silvestri E, Kayserili H, Zambruno G, Puddu P, D'Alessio M. Novel and recurrent mutations in the integrin beta 4 subunit gene causing lethal junctional epidermolysis bullosa with pyloric atresia. Exp Dermatol. 2003;12:716–20. [PubMed: 14705814]
17. Inoue M, Tamai K, Shimizu H, Owaribe K, Nakama T, Hashimoto T, McGrath JA. A homozygous missense mutation in the cytoplasmic tail of beta4 integrin, G931D, that disrupts hemidesmosome assembly and underlies Non-Herlitz junctional epidermolysis bullosa without pyloric atresia? J Invest Dermatol. 2000;114:1061–4. [PubMed: 10792571]
18. Jonkman MF, Pas HH, Nijenhuis M, Kloosterhuis G, Steege G. Deletion of a cytoplasmic domain of integrin beta4 causes epidermolysis bullosa simplex. J Invest Dermatol. 2002;119:1275–81. [PubMed: 12485428]
19. Jonkman MF, Schuur J, Dijk F, Heeres K, de Jong MC, van der Meer JB, Yancey KB, Pas HH. Inflammatory variant of epidermolysis bullosa acquisita with IgG autoantibodies against type VII collagen and laminin alpha3. Arch Dermatol. 2000;136:227–31. [PubMed: 10677099]
20. Kambham N, Tanji N, Seigle RL, Markowitz GS, Pulkkinen L, Uitto J, D'Agati VD. Congenital focal segmental glomerulosclerosis associated with beta4 integrin mutation and epidermolysis bullosa. Am J Kidney Dis. 2000;36:190–6. [PubMed: 10873890]
21. Kirkham J, Robinson C, Strafford SM, Shore RC, Bonass WA, Brookes SJ, Wright JT. The chemical composition of tooth enamel in junctional epidermolysis bullosa. Arch Oral Biol. 2000;45:377–86. [PubMed: 10739859]
22. Koss-Harnes D, Hoyheim B, Anton-Lamprecht I, Gjesti A, Jorgensen RS, Jahnsen FL, Olaisen B, Wiche G, Gedde-Dahl T. A site-specific plectin mutation causes dominant epidermolysis bullosa simplex Ogna: two identical de novo mutations. J Invest Dermatol. 2002;118:87–93. [PubMed: 11851880]
23. Koss-Harnes D, Hoyheim B, Jonkman MF, de Groot WP, de Weerdt CJ, Nikolic B, Wiche G, Gedde-Dahl T. Life-long course and molecular characterization of the original Dutch family with epidermolysis bullosa simplex with muscular dystrophy due to a homozygous novel plectin point mutation. Acta Derm Venereol. 2004;84:124–31. [PubMed: 15206692]
24. Kunz M, Rouan F, Pulkkinen L, Hamm H, Jeschke R, Bruckner-Tuderman L, Brocker EB, Wiche G, Uitto J, Zillikens D. Mutation reports: epidermolysis bullosa simplex associated with severe mucous membrane involvement and novel mutations in the plectin gene. J Invest Dermatol. 2000;114:376–80. [PubMed: 10652001]
25. Lepinard C, Descamps P, Meneguzzi G, Blanchet-Bardon C, Germain DP, Larget-Piet L, Beringue F, Berchel C, Muller F, Dumez Y. Prenatal diagnosis of pyloric atresia-junctional epidermolysis bullosa syndrome in a fetus not known to be at risk. Prenat Diagn. 2000;20:70–5. [PubMed: 10701857]
26. Lucky AW, Pfendner E, Pillay E, Paskel J, Weiner M, Palisson F. Psychosocial aspects of epidermolysis bullosa: Proceedings of the IInd International Symposium on Epidermolysis Bullosa, Santiago, Chile, 2005. Int J Dermatol. 2007;46:809–14. [PubMed: 17651161]
27. McLean WH, Pulkkinen L, Smith FJ, Rugg EL, Lane EB, Bullrich F, Burgeson RE, Amano S, Hudson DL, Owaribe K, McGrath JA, McMillan JR, Eady RA, Leigh IM, Christiano AM, Uitto J. Loss of plectin causes epidermolysis bullosa with muscular dystrophy: cDNA cloning and genomic organization. Genes Dev. 1996;10:1724–35. [PubMed: 8698233]
28. Mellerio JE, Pulkkinen L, McMillan JR, Lake BD, Horn HM, Tidman MJ, Harper JI, McGrath JA, Uitto J, Eady RA. Pyloric atresia-junctional epidermolysis bullosa syndrome: mutations in the integrin beta4 gene (ITGB4) in two unrelated patients with mild disease. Br J Dermatol. 1998;139:862–71. [PubMed: 9892956]
29. Mellerio JE, Weiner M, Denyer JE, Pillay EI, Lucky AW, Bruckner A, Palisson F. Medical management of epidermolysis bullosa: Proceedings of the IInd International Symposium on Epidermolysis Bullosa, Santiago, Chile, 2005. Int J Dermatol. 2007;46:795–800. [PubMed: 17651159]
30. Nakamura H, Sawamura D, Goto M, Nakamura H, McMillan JR, Park S, Kono S, Hasegawa S, Paku S, Nakamura T, Ogiso Y, Shimizu H. Epidermolysis bullosa simplex associated with pyloric atresia is a novel clinical subtype caused by mutations in the plectin gene (PLEC1). J Mol Diagn. 2005;7:28–35. [PMC free article: PMC1867514] [PubMed: 15681471]
31. Nakamura H, Sawamura D, Goto M, Sato-Matsumura KC, LaDuca J, Lee JY, Masunaga T, Shimizu H. The G2028R glycine substitution mutation in COL7A1 leads to marked inter-familiar clinical heterogeneity in dominant dystrophic epidermolysis bullosa. J Dermatol Sci. 2004;34:195–200. [PubMed: 15113589]
32. Nakano A, Pulkkinen L, Murrell D, Rico J, Lucky AW, Garzon M, Stevens CA, Robertson S, Pfendner E, Uitto J. Epidermolysis bullosa with congenital pyloric atresia: novel mutations in the beta 4 integrin gene (ITGB4) and genotype/phenotype correlations. Pediatr Res. 2001;49:618–26. [PubMed: 11328943]
33. Nakano A, Pfendner E, Hashimoto I, Uitto J. Herlitz junctional epidermolysis bullosa: novel and recurrent mutations in the LAMB3 gene and the population carrier frequency. J Invest Dermatol. 2000;115:493–8. [PubMed: 11023379]
34. Pasmooij AM, van der Steege G, Pas HH, Smitt JH, Nijenhuis AM, Zuiderveen J, Jonkman MF. Features of epidermolysis bullosa simplex due to mutations in the ectodomain of type XVII collagen. Br J Dermatol. 2004;151:669–74. [PubMed: 15377356]
35. Pfendner E, Uitto J. Plectin gene mutations can cause epidermolysis bullosa with pyloric atresia. J Invest Dermatol. 2005;124:111–5. [PubMed: 15654962]
36. Pfendner E, Rouan F, Uitto J. Progress in epidermolysis bullosa: the phenotypic spectrum of plectin mutations. Exp Dermatol. 2005;14:241–9. [PubMed: 15810881]
37. Pfendner EG, Bruckner A, Conget P, Mellerio J, Palisson F, Lucky AW. Basic science of epidermolysis bullosa and diagnostic and molecular characterization: Proceedings of the IInd International Symposium on Epidermolysis Bullosa, Santiago, Chile, 2005. Int J Dermatol. 2007;46:781–94. [PubMed: 17651158]
38. Pulkkinen L, Uitto J. Mutation analysis and molecular genetics of epidermolysis bullosa. Matrix Biol. 1999;18:29–42. [PubMed: 10367729]
39. Pulkkinen L, Bruckner-Tuderman L, August C, Uitto J. Compound heterozygosity for missense (L156P) and nonsense (R554X) mutations in the beta4 integrin gene (ITGB4) underlies mild, nonlethal phenotype of epidermolysis bullosa with pyloric atresia. Am J Pathol. 1998a;152:935–41. [PMC free article: PMC1858243] [PubMed: 9546354]
40. Pulkkinen L, Bullrich F, Czarnecki P, Weiss L, Uitto J. Maternal uniparental disomy of chromosome 1 with reduction to homozygosity of the LAMB3 locus in a patient with Herlitz junctional epidermolysis bullosa. Am J Hum Genet. 1997a;61:611–9. [PMC free article: PMC1715967] [PubMed: 9326326]
41. Pulkkinen L, Kimonis VE, Xu Y, Spanou EN, McLean WH, Uitto J. Homozygous alpha6 integrin mutation in junctional epidermolysis bullosa with congenital duodenal atresia. Hum Mol Genet. 1997b;6:669–74. [PubMed: 9158140]
42. Pulkkinen L, Kurtz K, Xu Y, Bruckner-Tuderman L, Uitto J. Genomic organization of the integrin beta 4 gene (ITGB4): a homozygous splice-site mutation in a patient with junctional epidermolysis bullosa associated with pyloric atresia. Lab Invest. 1997c;76:823–33. [PubMed: 9194858]
43. Pulkkinen L, Rouan F, Bruckner-Tuderman L, Wallerstein R, Garzon M, Brown T, Smith L, Carter W, Uitto J. Novel ITGB4 mutations in lethal and nonlethal variants of epidermolysis bullosa with pyloric atresia: missense versus nonsense. Am J Hum Genet. 1998b;63:1376–87. [PMC free article: PMC1377547] [PubMed: 9792864]
44. Puvabanditsin S, Garrow E, Samransamraujkit R, Lopez LA, Lambert WC. Epidermolysis bullosa associated with congenital localized absence of skin, fetal abdominal mass, and pyloric atresia. Pediatr Dermatol. 1997;14:359–62. [PubMed: 9336805]
45. Rezniczek GA, Abrahamsberg C, Fuchs P, Spazierer D, Wiche G. Plectin 5'-transcript diversity: short alternative sequences determine stability of gene products, initiation of translation and subcellular localization of isoforms. Hum Mol Genet. 2003;12:3181–94. [PubMed: 14559777]
46. Ruzzi L, Gagnoux-Palacios L, Pinola M, Belli S, Meneguzzi G, D'Alessio M, Zambruno G. A homozygous mutation in the integrin alpha6 gene in junctional epidermolysis bullosa with pyloric atresia. J Clin Invest. 1997;99:2826–31. [PMC free article: PMC508131] [PubMed: 9185503]
47. Schara U, Tucke J, Mortier W, Nusslein T, Rouan F, Pfendner E, Zillikens D, Bruckner-Tuderman L, Uitto J, Wiche G, Schroder R. Severe mucous membrane involvement in epidermolysis bullosa simplex with muscular dystrophy due to a novel plectin gene mutation. Eur J Pediatr. 2004;163:218–22. [PubMed: 14963703]
48. Takizawa Y, Pulkkinen L, Chao SC, Nakajima H, Nakano Y, Shimizu H, Uitto J. Mutation report: complete paternal uniparental isodisomy of chromosome 1: a novel mechanism for Herlitz junctional epidermolysis bullosa. J Invest Dermatol. 2000;115:307–11. [PubMed: 10951251]
49. Uitto J, Richard G, McGrath JA. Diseases of epidermal keratins and their linker proteins. Exp Cell Res. 2007;313:1995–2009. [PMC free article: PMC2578874] [PubMed: 17531221]
50. Varki R, Sadowski S, Pfendner E, Uitto J. Epidermolysis bullosa. I. Molecular genetics of the junctional and hemidesmosomal variants. J Med Genet. 2006;43:641–52. [PMC free article: PMC2564586] [PubMed: 16473856]
51. Varki R, Sadowski S, Uitto J, Pfendner E. Epidermolysis bullosa. II. Type VII collagen mutations and phenotype-genotype correlations in the dystrophic subtypes. J Med Genet. 2007;44:181–92. [PMC free article: PMC2598021] [PubMed: 16971478]
52. Wallerstein R, Klein ML, Genieser N, Pulkkinen L, Uitto J. Epidermolysis bullosa, pyloric atresia, and obstructive uropathy: a report of two case reports with molecular correlation and clinical management. Pediatr Dermatol. 2000;17:286–9. [PubMed: 10990577]
53. Yan EG, Paris JJ, Ahluwalia J, Lane AT, Bruckner AL. Treatment decision-making for patients with the Herlitz subtype of junctional epidermolysis bullosa. J Perinatol. 2007;27:307–11. [PubMed: 17363907]
54. Yoon SO, Shin S, Lipscomb EA. A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling. Cancer Res. 2006;66:2732–9. [PubMed: 16510594]

Author Notes

Web: www.genedx.com

Web: www.cincinnatichildrens.org/eb-center

Revision History

• 28 April 2009 (cd) Revision: PLEC1 testing clinically available; prenatal testing available

• 22 February 2008 (me) Review posted to live Web site

• 10 May 2007 (egp) Original submission